Biotech investing isn't easy, though. Clinical-trial failures, expiring patents, and stiff competition mean there's plenty of risk associated with owning biotech stocks. Nevertheless, the potential rewards associated with investing in the industry could make owning stocks with upcoming catalysts a great idea. For example, BioMarin (NASDAQ: BMRN), Iovance Biotherapeutics (NASDAQ: IOVA), and Immunomedics (NASDAQ: IMMU) have events coming up that could make buying shares this year smart.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,